Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Publication Number
US-11147780-B2
Publication Date
2021-10-19
Expiration Date
Abstract
Disclosed herein is a multidrug pain management package to dispense two or more medicaments to treat pain comprising a primary n-polygon, and one or more concentric m-polygons, wherein each side of the n-polygon and m-polygons have at least n or m-medicament chambers capable of holding the two or more medicaments. Also disclosed herein is a multidrug pain management package comprising a disk, wherein the disk is divided into equally spaced regions, and wherein each region has chambers capable of holding medicaments. Also disclosed herein are single formulations to treat pain.
Core Innovation
The patent provides a single formulation for pain management that includes acetaminophen, one or more nonsteroidal anti-inflammatory drug, and a gabapentinoid. The formulation further includes at least two additional active ingredients selected from alpha 2 agonists, corticosteroids, H2 blockers, proton pump inhibitors, antacids, SSRIs, SNRIs, sleep aids drugs, natural sleep aids, magnesium, zinc, vitamin C, vitamin D, and tramadol.
The patent also describes a pain-management dispenser package that organizes and dispenses two or more pain medicaments. The dispenser package is based on geometric blister-layer layouts, including a primary n-polygon with concentric m-polygon regions, or a disk-shaped blister layer divided into equally spaced regions, and includes rupturable sealed chambers with a medicament canopy and thermoplastic blister materials.
The disclosure includes delivery approaches for the single formulation, including an inhaler configured to dispense the single formulation. It also describes a proposed clinical example using non-opioid regimens with pain self-reporting (NRS-11), a use context for COVID-19-associated pain, and multiple dosage tables for adult and children and for different pain scenarios.
Claims Coverage
The provided portion includes five independent claims. The claims focus on a single formulation for pain that combines acetaminophen, one or more nonsteroidal anti-inflammatory drug, and a gabapentinoid, with additional defined active-ingredient sets and specific constraints on administration or dispensing for certain claims.
A single formulation with fixed multi-agent active set
A single formulation consisting of acetaminophen; one or more nonsteroidal anti-inflammatory drug; a gabapentinoid; and at least two additional active ingredients selected from alpha 2 agonists, corticosteroids, H2 blockers, proton pump inhibitors, antacids, SSRIs, SNRIs, sleep aids drugs, natural sleep aids, magnesium, zinc, vitamin C, vitamin D, and tramadol.
First-day administration on an eight-hour schedule
A single formulation consisting of acetaminophen; one or more nonsteroidal anti-inflammatory drug; a gabapentinoid; and at least two additional active ingredients selected from the stated group, wherein the single formulation is given to a patient on the first day every eight hours.
Inhaler-based dispensing of the single formulation
A single formulation consisting of acetaminophen; one or more nonsteroidal anti-inflammatory drug; a gabapentinoid; and at least two additional active ingredients selected from the stated group, wherein the single formulation is dispensed by an inhaler to a patient.
A corticosteroid and H2 blocker included formulation
A single formulation consisting of acetaminophen; one or more nonsteroidal anti-inflammatory drug; a gabapentinoid; one or more corticosteroids; and one or more H2 blockers.
A limited set of additional active ingredients
A single formulation consisting of acetaminophen; one or more nonsteroidal anti-inflammatory drug; a gabapentinoid; and at least two additional active ingredients selected from corticosteroids, H2 blockers, magnesium, zinc, vitamin C, and vitamin D.
Across the provided independent claims, the patent claims a single formulation for pain that combines acetaminophen, a nonsteroidal anti-inflammatory drug, and a gabapentinoid, paired with either an expanded group of additional active ingredients, or specific additional ingredient selections such as corticosteroids plus H2 blockers, or a narrower additional-ingredient set. Certain claims further add limitations related to administration on the first day every eight hours and dispensing by an inhaler.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Pain management.
COVID-19-associated pain.
Interested in licensing this patent?